Stay updated on Aducanumab for Early Alzheimer's: Clinical Trial
Sign up to get notified when there's something new on the Aducanumab for Early Alzheimer's: Clinical Trial page.

Latest updates to the Aducanumab for Early Alzheimer's: Clinical Trial page
- Check5 days agoChange DetectedThe page now presents the ClinicalTrials.gov record for Biogen’s Phase 3 EMERGE aducanumab study for early Alzheimer’s disease. It includes the study’s terminated status, design and outcome measures, eligibility and locations, and study documents.SummaryDifference100%

- Check12 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA site-wide NIH transition notice appears above the 403 error page, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe footer now displays website revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden message and minimal navigation, removing access to the full study record details and related resources.SummaryDifference17%

- Check61 days agoChange DetectedThe page shows Revision: v3.7.0 replacing Revision: v3.6.6. This represents a system or UI update, not changes to the study text.SummaryDifference0.0%

Stay in the know with updates to Aducanumab for Early Alzheimer's: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Aducanumab for Early Alzheimer's: Clinical Trial page.